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OBJECTIVE — We investigated the natural history of glucokinase (GCK)-related maturity-
onsetdiabetesoftheyoungtype2(MODY2),notablythefactorsassociatedwithdeteriorationof
hyperglycemia over time.
RESEARCH DESIGN AND METHODS — We report an 11-year follow-up of glucose
tolerance and indexes of insulin secretion and insulin sensitivity derived from oral glucose
tolerance tests in 33 MODY2 subjects.
RESULTS — Thevariationbetweentestsofglucosetolerance(expressedastheareaunderthe
glucose curve) was 6.9  3.2% (mean  SEM), but individual results ranged from 20 to 61%.
Deterioration of glucose tolerance between tests was associated with decreased insulin sensitiv-
ity, while insulin secretion remained stable.
CONCLUSIONS — Glucose tolerance can remain stable over many years in subjects with
MODY2duetotherelativestabilityoftheGCK-related-celldefect.However,thedevelopment
ofinsulinresistancemayhaveanimportantroleinthedeteriorationoftheglucosetoleranceand
in the long-term evolution of the disorder.
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M
aturity-onset diabetes of the
young type 2 (MODY2) is a famil-
ial form of hyperglycemia caused
by heterozygous mutations in the gene
encoding glucokinase (GCK) (1). Hyper-
glycemia related to GCK mutations re-
sults from defects in glucose-stimulated
insulinsecretion(2)andhepaticsynthesis
of glycogen from glucose (3). The hyper-
glycemia of MODY2 is often mild. Most
patients have impaired fasting glucose or
impairedglucosetolerance,and50%of
affected individuals have overt diabetes
(1). To investigate the natural history of
MODY2, and notably the factors associ-
ated with deterioration of hyperglycemia,
we retrospectively analyzed hospital
recordsof33MODY2subjects.Wereport
an 11-year follow-up of glucose tolerance
and of indexes of insulin secretion and
insulin sensitivity derived from oral glu-
cose tolerance tests (OGTTs).
RESEARCH DESIGN AND
METHODS— We studied 17 women
and 16 men from 14 MODY2 kindred of
French ancestry who had undergone two
OGTTs with insulin measurement,
spaced by at least 4 years. GCK mutations
wereconﬁrmedbydirectsequencing(on-
line appendix Table 1 [available at http://
dx.doi.org/10.2337/dc07-2017]). The
area under the curve (AUC) relating glu-
cose or insulin levels and the time during
the OGTT was calculated by the trapezoi-
dal rule. Glucose tolerance was expressed
as AUCglucose. Variation of AUCglucose be-
tween tests (AUCglucose) was computed
as the difference between values at the
second and ﬁrst OGTTs, expressed as a
percent of the value at the ﬁrst OGTT.
Variations of other clinical and biological
parameters between tests were calculated
similarly. Indexes of -cell function were
computed as the ratios of AUCinsulin to
AUCglucose and insulin30–0min to
glucose30min (4). Insulin sensitivity was
assessed by Matzuda’s composite insulin
sensitivity index (5). Homeostasis model
assessment (HOMA) indexes of -cell
function(%B)andinsulinsensitivity(%S)
were also computed. Results are ex-
pressed as means  SEM.
RESULTS— The average follow-up
period, deﬁned as the interval between
OGTTs,was11.01.1years(range4.3–
25.1). Clinical and OGTT data are shown
in Table 1 and in online appendix Fig. 1.
Both fasting and 2-h glucose levels were
slightly but signiﬁcantly increased in the
secondcomparedwiththeﬁrstOGTT.In-
dexes of insulin secretion were similar at
the ﬁrst and second OGTTs. Insulin sen-
sitivity was signiﬁcantly decreased at the
second OGTT. All quantitative clinical or
biological parameters were signiﬁcantly
correlated at the ﬁrst and second OGTTs
(Table 1).
Although the average AUCglucose was
only mildly increased between tests (vari-
ation 6.9  3.2%), individual results of
AUCglucosewereheterogeneous,ranging
20 to 61% (online appendix Fig. 2). To
investigate parameters associated with
AUCglucose heterogeneity, we compared
subjects whose glucose tolerance re-
mained stable or had improved during
follow-up with subjects whose glucose
tolerancehaddeteriorated(onlineappen-
dix Table 2). Groups were deﬁned by a
AUCglucose below or above the median
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Subjectswhoseglucosetolerancedeterio-
rated were older at the second OGTT
(38  4 vs. 27  4 years, P  0.02) and
had a longer follow-up (14  2 vs. 8  1
years,P0.007).AUCglucosecorrelated
both with age at the second OGTT (R
2 
0.17; P  0.01) and with the duration of
follow-up(R
20.16;P0.01).Subjects
whose glucose tolerance deteriorated had
a higher BMI increase during follow-up,
but the differences were not statistically
signiﬁcant. However, insulin sensitivity
was correlated with BMI at the second
OGTT (r
2  0.19; P  0.01).
Subjects whose glucose tolerance de-
teriorated showed signiﬁcantly decreased
HOMA%S during follow-up compared
with subjects whose glucose tolerance re-
mained stable (27  12% vs. 18 
15%,P0.04).Theyalsoshowedatrend
toward higher AUCinsulin. These obser-
vations are best explained by a deteriora-
tion of insulin sensitivity between tests in
the former group. The variation of
HOMA%B index of insulin secretion be-
tween tests was not signiﬁcantly different
in the two groups of subjects (16  10%
vs. 6  10%, P  0.49).
CONCLUSIONS — This is the ﬁrst
systematic follow-up study of the natural
history of MODY2. Our results suggest
that glucose tolerance can remain stable
over the course of many years in subjects
with this form of diabetes. This may be
related to the relative stability of the glu-
cokinase-related -cell defect, as insulin
secretion in MODY2 subjects does not
seem to aggravate substantially over time.
However,iforwheninsulinresistancede-
velops, the -cell defect may prevent an
adequate compensatory increase in insu-
lin secretion, resulting in a deterioration
of the glucose tolerance. We have previ-
ously documented that insulin resistance
is frequent in subjects with MODY2 (6).
Our present results suggest that it may
have an important role in the deteriora-
tion of the glucose tolerance and in the
long-term evolution of the disorder.
These results contrast with those ob-
served in MODY1 (HNF4A) and MODY3
(HNF1A), associated with a progressive
decrease of insulin secretion and severe
deterioration of hyperglycemia (7,8).
Insulin sensitivity is inﬂuenced by
polygenic determinants interacting with
multiple environmental factors. Putative
unfavorable alleles are probably frequent
in the general population, given the in-
creasing worldwide prevalence of type 2
diabetes associated with changes in life-
style. These unfavorable alleles could af-
fect the clinical phenotype of MODY2
subjects.Theiridentiﬁcationmayprovide
abetterunderstandingoftheroleofmod-
iﬁer genes in the clinical progression of
monogenic types of diabetes. Regarding
treatment, in most MODY2 cases, diet
therapy satisfactorily controls blood glu-
cose levels and no hypoglycemic medica-
tion is required (1). However, as for all
patients with diabetes, subjects with
MODY2 should be instructed not to gain
excessive weight and to have a regular
physical activity to avoid the develop-
ment or aggravation of insulin resistance.
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OGTT PR
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2) 19.2  0.5 22.3  0.6 — — —
BMI (Z score) 0.16  0.15 0.08  0.20 0.04 0.69 0.0001
Hyperglycemic status: IFG/IFG-IGT/diabetes (%) 30/33/37 15/30/55 0.23 — —
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HOMA%B (%) 49  35 2  3 0.50 0.12 0.03
HOMA%S (%) 133  12 101  8 0.01 0.34 0.0002
ISIcomp 6.38  0.82 4.56  0.38 0.01 0.45 0.0001
Data are means  SEM unless otherwise indicated (n  33). Statistics (P) are paired Student’s t test on log-transformed data or Fisher’s exact test (qualitative traits).
R
2 are correlation coefﬁcients of bivariate linear ﬁt relating values at ﬁrst and second OGTT with ad hoc statistics (P*). ISIcomp is expressed in arbitrary units. FPG,
fastingplasmaglucose;IFG,impairedfastingglucose;IFG-IGT,combinedimpairedfastingglucoseandimpairedglucosetolerance;OHA,oralhypoglycemicagents,
†sulfonylurea (n  3)/metformin (n  2). HOMA%B and HOMA%S were computed with the HOMA Calculator (version 2.2) available at http://www.dtu.ox.ac.uk/
index.php?maindoc/homa/index.php.
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